162 related articles for article (PubMed ID: 8224241)
1. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Mattar T; Kochhar K; Bartlett R; Bremer EG; Finnegan A
FEBS Lett; 1993 Nov; 334(2):161-4. PubMed ID: 8224241
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Xu X; Shen J; Mall JW; Myers JA; Huang W; Blinder L; Saclarides TJ; Williams JW; Chong AS
Biochem Pharmacol; 1999 Nov; 58(9):1405-13. PubMed ID: 10513984
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Mirmohammadsadegh A; Homey B; Abts HF; Köhrer K; Ruzicka T; Michel G
Biochem Pharmacol; 1998 May; 55(9):1523-9. PubMed ID: 10076546
[TBL] [Abstract][Full Text] [Related]
5. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Doscas ME; Williamson AJ; Usha L; Bogachkov Y; Rao GS; Xiao F; Wang Y; Ruby C; Kaufman H; Zhou J; Williams JW; Li Y; Xu X
Neoplasia; 2014 Oct; 16(10):824-34. PubMed ID: 25379019
[TBL] [Abstract][Full Text] [Related]
7. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
8. Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.
Zielinski T; Müller HJ; Bartlett RR
Agents Actions; 1993; 38 Spec No():C80-2. PubMed ID: 8317329
[TBL] [Abstract][Full Text] [Related]
9. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
Wang J; Sun J; Hu J; Wang C; Prinz RA; Peng D; Liu X; Xu X
FASEB J; 2020 Aug; 34(8):10132-10145. PubMed ID: 32598086
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
Manna SK; Aggarwal BB
J Immunol; 1999 Feb; 162(4):2095-102. PubMed ID: 9973483
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
Hossain MM; Margolis DM
J Acquir Immune Defic Syndr; 2001 Oct; 28(2):199-201. PubMed ID: 11588518
[No Abstract] [Full Text] [Related]
12. Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes.
Latchoumycandane C; Seah QM; Tan RC; Sattabongkot J; Beerheide W; Boelsterli UA
Toxicol Appl Pharmacol; 2006 Nov; 217(1):125-33. PubMed ID: 16979204
[TBL] [Abstract][Full Text] [Related]
13. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Palmer G; Burger D; Mezin F; Magne D; Gabay C; Dayer JM; Guerne PA
Arthritis Res Ther; 2004; 6(3):R181-9. PubMed ID: 15142263
[TBL] [Abstract][Full Text] [Related]
14. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Vergne-Salle P; Léger DY; Bertin P; Trèves R; Beneytout JL; Liagre B
Cytokine; 2005 Sep; 31(5):335-48. PubMed ID: 16099671
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
16. Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture.
Ju DW; Zheng QY; Wang HB; Fang J
Zhongguo Yao Li Xue Bao; 1994 May; 15(3):223-6. PubMed ID: 7976375
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.
Miljkovic Dj; Samardzic T; Drakulic D; Stosic-Grujicic S; Trajkovic V
Cytokine; 2002 Aug; 19(4):181-6. PubMed ID: 12297111
[TBL] [Abstract][Full Text] [Related]
18. Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.
Jankovic V; Samardzic T; Stosic-Grujicic S; Popadic D; Trajkovic V
Cell Immunol; 2000 Feb; 199(2):73-80. PubMed ID: 10698616
[TBL] [Abstract][Full Text] [Related]
19. The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.
Elder RT; Xu X; Williams JW; Gong H; Finnegan A; Chong AS
J Immunol; 1997 Jul; 159(1):22-7. PubMed ID: 9200434
[TBL] [Abstract][Full Text] [Related]
20. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Hamilton LC; Vojnovic I; Warner TD
Br J Pharmacol; 1999 Aug; 127(7):1589-96. PubMed ID: 10455314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
